ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

Sarcoidosis Clinical Trial

Official title:

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02155803
• Other study ID #: AMCMAJCA2014
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• First received: May 30, 2014
• Last updated: January 23, 2015
• Start date: February 2015
• Est. completion date: November 2015

Study information

• Verified date: January 2015
• Source: Albany Medical College
• Contact: Haroon Chaudhry, MBBS
• Phone: 518-262-1542
• Email: chaudhh[@]mail.amc.edu
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

ACTHAR Gel has activity in sarcoidosis associated hypercalciuria and calcium dysregulation.

Description:

Sarcoidosis is a multisystem granulomatous disease of unknown cause. Although sarcoidosis most commonly affects the lung, it may affect any organ. Although corticosteroids are recognized as the drug of choice for sarcoidosis. ACTH(adrenocorticotropic hormone) is the only drug that is FDA-approved for this disorder. However, there is limited data on the efficacy of ACTH for this condition.

Calcium metabolism is disregulated in active sarcoidosis. The primary abnormality in calcium metabolism stems from an increased 1-α hydroxylase activity in sarcoid alveolar macrophages that converts 25-hydroxyvitamin D to 1, 25-dihydroxyvitamin D, the active form of the vitamin. This can result in hypercalcemia, hypercalciuria, nephrocalcinosis, nephrolithiasis, interstitial nephritis, glomerulonephritis, acute and chronic kidney disease. Importantly, almost of the renal manifestations stem from disordered calcium metabolism. Unlike other organ manifestations of sarcoidosis, the disorder of calcium metabolism is more common in whites compared to african americans.Compared to hypercalcemia, hypercalciuria is three times more common in sarcoidosis, nevertheless, it has largely been ignored.

In general, the patient with hypercalcemia should be advised to avoid sunlight, curtail intake of major sources of dietary calcium and vitamin D, and drink ample fluids.If the patient is symptomatic, serum calcium is greater than 11 mg/dl, the serum creatinine is elevated, or the patient has nephrolithiasis, drug therapy is usually required. The drug of choice is prednisone at an initial daily dose of 20 - 40 mg/day.Unfortunately, prolonged corticosteroid therapy may result in unacceptable side effects including osteoporosis. This is particularly important as elevated calcitriol observed in patients with sarcoidosis can further jeopardize bone structure by resorption. Alternative medications that have shown benefit for sarcoidosis associated calcium dysregulation have included chloroquine,hydroxychloroquine, ketoconazole.

Not only may ACTHER GEL have obvious anti-inflammatory effects by resulting in corticosteroid production, but it may also activate melanocortin receptors. The melanocortin system has powerful anti-inflammatory properties that may be beneficial in the treatment of sarcoidosis.

We believe that there are several specific advantages of assessing the effectiveness of anti-sarcoidosis therapy by examining sarcoidosis-associated disorders of calcium metabolism.

1. The measures of granulomatous activity (serum calcium, urinary calcium, serum 25-hydroxyvitamin D, and serum 1, 25-dihydroxyvitamin D levels) are directly related to the granulomatous inflammation of sarcoidosis.

2. These parameters can be accurately and objectively quantified. This is an important issue in sarcoidosis as the endpoint for involvement of the lungs, skin, and eyes is problematic because it is either inexact and/or not unidimensional.

3. These constituents can be easily used to clinically monitor sarcoidosis. This is not the case for other forms of sarcoidosis including involvement of the lung and skin.

• Although hypercalciuria and disordered calcium metabolism is not as common a manifestation of sarcoidosis as lung involvement, there is little evidence that the anti-granulomatous response to this disease is organ specific. In a randomized double-blind placebo control trial of infliximab for pulmonary sarcoidosis, extrapulmonary sarcoidosis also responded to this therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: November 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age greater than 18 years old.

2. Able to understand English to the point of comprehending the informed consent form.

3. Biopsy proven sarcoidosis.

4. Documented hypercalciuria (urinary excretion of > 4mg/kg of calcium/day) or hypercalcemia within 4 weeks of study entry.

5. Historical evidence that the patient's hypercalciuria/hypercalcemia is related to sarcoidosis. This should include a serum parathyroid hormone (PTH) level which is not elevated.

Exclusion Criteria:

1. A change in anti-sarcoidosis medications within 3 months of study entry.

2. A history of hyperparathyroidism or another non-sarcoidosis cause of hypercalcemia/hypercalciuria

3. A history of Cushing's disease.

4. Have a diagnosis of a medical disorder other than sarcoidosis that in the opinion of the investigator would complicate the evaluation of response treatment.

5. Have used any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.

6. Use of loop or thiazide diuretics for hypertension or other disorders.

7. Chronic use of antacids.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypercalcemia
• Hypercalcemia Due to Sarcoidosis
• Sarcoidosis

Intervention

Drug:
• ACTHAR Gel (adrenocorticotropic hormone)
ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks

Locations

Country	Name	City	State
United States	Albany Medical College	Albany	New York

Sponsors (1)

Lead Sponsor	Collaborator
Albany Medical College

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of 24 hour urine calcium	Reduction of 24 hour urine calcium in patients with sarcoidosis associated hypercalciuria (primary endpoint) between week 0 and week 12.	Between week 0 and week 12.	No
Secondary	Change in serum calcium during 12 week ACTHAR GEL treatment		Baseline compared to 12 weeks.	No
Secondary	Change in 1,25 di-hydroxy Vitamin D during 12 week ACTHAR GEL treatment		Baseline compared to 12 weeks.	No
Secondary	Change in patient global VAS during 12 week ACTHAR GEL treatment		Baseline to 12 weeks	No
Secondary	Change in physician global VAS during 12 week ACTHAR GEL treatment		Baseline to 12 Weeks	No
Secondary	Change in urinary symptoms during 12 week ACTHAR GEL treatment		Baseline to 12 Weeks	No
Secondary	Change in Short Form-36 during 12 week ACTHAR GEL treatment		Baseline to 12 Weeks	No
Secondary	Change in Sarcoidosis Health Questionnaire during 12 week ACTHAR GEL treatment		Baseline to 12 Weeks	No
Secondary	Change in eCOST during 12 week ACTHAR gel treatment		Baseline to 12 Weeks	No
Secondary	Change in adjusted eCOST (eCOSTadj) calculated as the eCOST/# organs with an eCOST score > 022 during 12 week ACTHAR gel treatment		Baseline to 12 Weeks	No